A Quantitative MRI Study of Prostate Cancer Before and After Radiation Therapy

2004 ◽  
Author(s):  
David L. Buckley
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Quantitative Mri ◽  
Before And After ◽  
Mri Study

Symptoms and Quality of Life in Men Before and After Radiation Therapy for Prostate Cancer

2012 ◽  
Vol 84 (3) ◽  
pp. S210-S211
Author(s):  
W.W. Wong ◽  
S.R. Dirksen ◽  
M.R. Belyea
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Radiation Therapy ◽  
Before And After

scholarly journals Erectile Tissue Quantitative DCE-MRI Parameters and Sexual Function Before and After Radiation Therapy in Men With Prostate Cancer

2015 ◽  
Vol 93 (3) ◽  
pp. E219-E220
Author(s):  
M. Patel ◽  
R. Stoyanova ◽  
D. Kwon ◽  
S. Abraham ◽  
K.R. Padgett ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Sexual Function ◽  
Dce Mri ◽  
Erectile Tissue ◽  
Before And After

scholarly journals Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Abigail Pepin ◽  
Sarthak Shah ◽  
Monica Pernia ◽  
Siyuan Lei ◽  
Marilyn Ayoob ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Median Time ◽  
Bleeding Risk ◽  
Localized Prostate Cancer ◽  
External Beam Radiation ◽  
Beam Radiation ◽  
Antiplatelet Medication ◽  
Before And After

PurposePatients on anticoagulant/antiplatelet medications are at a high risk of bleeding following external beam radiation therapy for localized prostate cancer. SBRT may reduce the bleeding risk by decreasing the volume of bladder/rectum receiving high doses. This retrospective study sought to evaluate the rates of hematuria and hematochezia following SBRT in these patients.MethodsLocalized prostate cancer patients treated with SBRT from 2007 to 2017 on at least one anticoagulant/antiplatelet at baseline were included. The minimum follow-up was 3 years with a median follow-up of 72 months. Patients who had a rectal spacer placed prior to SBRT were excluded. Radiotherapy was delivered in 5 fractions to a dose of 35 Gy or 36.25 Gy utilizing the CyberKnife system. Hematuria and hematochezia were prospectively assessed before and after treatment using the Expanded Prostate Cancer Index Composite (EPIC-26). Toxicities were scored using the CTCAE v4. Cystoscopy and colonoscopy findings were retrospectively reviewed.ResultsForty-four men with a median age of 72 years with a history of taking at least one anticoagulant and/or antiplatelet medication received SBRT. Warfarin (46%), clopidogrel (34%) and rivaroxaban (9%) were the most common medications. Overall, 18.2% experienced hematuria with a median time of 10.5 months post-SBRT. Altogether, 38.6% experienced hematochezia with a median time of 6 months post-SBRT. ≥ Grade 2 hematuria and hematochezia occurred in 4.6% and 2.5%, respectively. One patient required bladder neck fulguration and one patient underwent rectal cauterization for multiple non-confluent telangiectasia. There were no grade 4 or 5 toxicities. Cystoscopy revealed bladder cancer (40%) and benign prostatic bleeding (40%) as the most common hematuria etiology. Colonoscopy demonstrated hemorrhoids (54.5%) and radiation proctitis (9.1%) as the main causes of hematochezia. There was no significant change from the mean baseline EPIC-26 hematuria and hematochezia scores at any point during follow up.ConclusionIn patients with baseline anticoagulant usage, moderate dose prostate SBRT was well tolerated without rectal spacing. High grade bleeding toxicities were uncommon and resolved with time. Baseline anticoagulation usage should not be considered a contraindication to prostate SBRT.

Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study

2018 ◽  
Vol 32 (2) ◽  
pp. e4048 ◽  
Author(s):  
Shirin Sabouri ◽  
Silvia D. Chang ◽  
S. Larry Goldenberg ◽  
Richard Savdie ◽  
Edward C. Jones ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Accuracy ◽  
Quantitative Mri ◽  
Dynamic Contrast Enhanced Mri ◽  
Dynamic Contrast Enhanced ◽  
Enhanced Mri ◽  
Diffusion Weighted ◽  
Contrast Enhanced ◽  
Mri Study ◽  
Contrast Enhanced Mri

EP-1293: Computed tomography perfusion of prostate cancer before and after radiation therapy: Early experience results

2014 ◽  
Vol 111 ◽  
pp. S86
Author(s):  
G.I. Boboc ◽  
V. Donato ◽  
M. Osimani ◽  
A. Laghi ◽  
A.L. Pastore ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Radiation Therapy ◽  
Early Experience ◽  
Computed Tomography Perfusion ◽  
Before And After

scholarly journals Assessment of Toxicity After 68Ga-PSMA-PET-Imaging Based Treatment Planning and Dose-Escalation in Radiation Therapy in Prostate Cancer Patients

2021 ◽  
Author(s):  
Kilian Schiller ◽  
Sabrina Dewes ◽  
Lisa Pfetsch ◽  
Marco MME Vogel ◽  
Michal Devecka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Pet Imaging ◽  
Tumor Control ◽  
Patient Centered ◽  
Psma Pet ◽  
Before And After ◽  
Pre Treatment ◽  
Grade 3

Abstract PURPOSE: Effective tumor control in prostate cancer demands elevated radiation doses given its low alpha/beta ratio. We investigated in primary and recurrent prostate cancer whether dose-escalated-radiation therapy (DE-RT) based on 68Ga-PSMA-PET positive lesions yields increased toxicity. METHODS: We evaluated 90 patients (salvage DE-RT: 67 patients, DE-re-RT: 11 patients, definite DE-RT: 12 patients) who were treated based on a pre-treatment hybrid 68Ga-PSMA. Findings from pre-treatment hybrid 68Ga-PSMA-PET could result in an adaption of radiation planning. Common Toxicity Criteria of Adverse Effects (Version 4.03) were used to assess toxicity, this was done before the initiation and at the end of DE-RT, as well as at the first and last follow-up (F/U) examination. We evaluated the change in toxicity for each interval for the collective as well as in a per-patient analysis.RESULTS: Findings in 68Ga-PSMA-PET-imaging resulted in a change of TNM-stage in 61.1% and an adapted treatment concept in 71.1% of patients. When comparing overall toxicity before DE-RT and at the last follow-up, 5.9% treatment-related side effects (grade 1-3) occurred with 1.7% of them being severe (grade 3). In a patient-centered approach we examined the intra-individual changes in toxicity before and after DE-RT. At the last F/U, the majority out of 80 patients (range: 61.3-93.8%) stated unchanged toxicity rates compared to the toxicity examined at the initiation of RT.CONCLUSION: The rate of treatment-related toxicity (grade 1-2) due to DE-RT in our cohort is 4.2%. For grade 3 toxicity it is 1.7%, respectively. The overall level of toxicity is highest during and shortly after completion of DE-RT (+7.4%) and improves over time until the last reported F/U (+5.9%). Compared to historical data, the toxicity profile of DE-RT is not increased. Therefore it is possible to apply DE-RT with the aim to increase tumor control by precisely treating all involved areas according to PSMA-PET-imaging.

Serial evaluation of sexual function before and after 3D conformal radiation therapy for prostate cancer

2000 ◽  
Vol 48 (3) ◽  
pp. 252
Author(s):  
C.T Chen ◽  
R.K Valicenti ◽  
T DeRose ◽  
J.D Lu ◽  
S.E Strup ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Sexual Function ◽  
Conformal Radiation Therapy ◽  
Before And After ◽  
3D Conformal Radiation Therapy ◽  
Serial Evaluation

395: Nomogram Predicting 10 year Life Expectancy after Radical Prostatectomy or Radiation Therapy for Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 131-132 ◽  
Author(s):  
Jochen Wafz ◽  
Andrea Gallina ◽  
Aldo M. Bocciardi ◽  
Sascha Ahyai ◽  
Paul Perrotta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Radical Prostatectomy ◽  
Life Expectancy
Sign in / Sign up

Export Citation Format

Share Document